Neogenomics (NEO) FY2025 10-K Risk Factors: 11 New, 7 Dropped

What the changes say

Neogenomics faces new operational risks from implementing a Laboratory Information Management System and adopting artificial intelligence technologies.
Supply chain dependencies, international trade tariffs, and clinical trial liabilities threaten financial and operating results.
The company highlights risks related to convertible notes and intellectual property protection.

What changed since the prior 10-K

New

NewRisks Relating to Our Business and Operations
If our products do not meet the expectations of our clients and patients, our reputation, business and operating results could suffer
Errors in our diagnostic testing or consultative services could cause improper patient treatment, harming our reputation and resulting in legal claims.
NewRisks Relating to Our Business and Operations
Our provision of laboratory testing and related services in support of sponsor-led clinical trials and research studies may expose us to contractual, operational, regulatory, or reputational risks, including risks related to data integrity, turnaround times, and compliance with applicable quality standards
Supporting clinical trials exposes us to data integrity, turnaround time, and compliance risks that could cause harm to study volunteers or delay drug market entry.
NewRisks Relating to Our Business and Operations
clinical trials in accordance with the FDA, the U.S. Drug Enforcement Agency (“DEA”), and other applicable regulations, including good clinical practice and informed consent requirements, could result in disruptions to our operations
Contractual indemnification provisions may not fully protect us against liabilities arising from gross negligence or misconduct in our clinical trial services.
NewRisks Relating to Our Business and Operations
Business disruptions, including due to natural disasters, power loss, break-ins, global conflicts, political unrest, or unstable economic and market conditions, could have a material adverse effect on our business, results of operations, financial condition, and stock price
Disasters and severe weather could disrupt our headquarters in Fort Myers, Florida and dry laboratories lack emergency back-up generators.
NewRisks Relating to Our Business and Operations
International trade disputes, including United States trade tariffs and retaliatory tariffs, could adversely impact our overall financial condition, results of operations, or cash flows
U.S. trade tariffs and retaliatory tariffs in international markets like the UK could increase material costs and reduce our margins.
NewRisks Relating to Our Business and Operations
We depend on third parties for our laboratory and research equipment and supplies. If these supplies or services become unavailable or are disrupted, we would have to seek alternate suppliers, and we may not be able to successfully perform our research, operate our business, or perform our tests on a timely basis
Long-term global supply chain disruptions could prevent us from obtaining laboratory equipment and reagents like sequencers on a timely basis.
NewRisks Relating to Our Business and Operations
Our current and potential future use of artificial intelligence and machine learning may not be successful and introduces emerging risks and challenges to our business
Using artificial intelligence across our lab services and financial functions introduces risks of biased datasets, compliance violations, and novel cybersecurity attacks.
NewRisks Relating to Our Business and Operations
including protected health information. AI and machine learning technologies may also contribute to novel and urgent cybersecurity risks, including through the use by third parties of such technologies to launch more automated, targeted, and coordinated attacks
Developing artificial intelligence systems increases our computing and operating costs and subjects us to a rapidly evolving regulatory framework.
NewRisks Relating to Our Business and Operations
If we are unable to successfully manage the implementation of our Laboratory Information Management System (“LIMS”), our business and results of operations may be adversely affected
Implementing our new Laboratory Information Management System is complex and time-consuming, risking information loss and operational disruption.
NewRisks Relating to Government Regulation and Reimbursement
We may form strategic partnerships or make investments in companies or technologies that could negatively affect our operating results, distract management’s attention from other business concerns, dilute our stockholders’ ownership, and significantly increase our debt, costs, expenses, liabilities and risks
Forming strategic partnerships or investments may distract management, dilute stockholders, and increase our debt, costs, and liabilities.
NewRisks Relating to Government Regulation and Reimbursement
investments in other companies, which could have a material negative effect on our results of operations and financial condition
Financing strategic partnerships through debt or stock issuance could harm our financial condition and dilute existing stockholders.

Dropped

DroppedRisks Relating to Our Business
We may become involved in litigation, and our insurance may not sufficiently cover all claims brought against us, which will increase our expenses and may adversely affect our business and results of operations
DroppedRisks Relating to Our Business
Our involvement with clinical trials and research services creates a risk of liability
DroppedRisks Relating to Our Business
Our investments in marketable securities are subject to certain risks which could affect our overall financial condition, results of operations, or cash flows
DroppedRisks Relating to Our Business
If our facilities become damaged or inoperable due to disasters, power loss, break-ins or similar events, we may be unable to continue our operations or our services could be interrupted or delayed, which could have a material adverse effect on our business, results of operations, and financial condition
DroppedRisks Relating to Government Regulation and Reimbursement
engineering controls such as safety needles, if found to be effective at reducing the risk of needlestick injuries in the workplace
DroppedRisks Relating to Government Regulation and Reimbursement
We may be unable to realize estimated benefits from our cost reduction and restructuring efforts and our profitability may be hurt or our business might otherwise be adversely affected
DroppedRisks Relating to Government Regulation and Reimbursement
We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets

Reworded

90% rewrittenRisks Relating to Our Business and Operations
We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business
Added context detailing that the company has been and may be party to intellectual property litigation and that patent enforcement is costly.
71% rewrittenRisks Relating to Government Regulation and Reimbursement
If the FDA were to begin to regulate Laboratory Developed Tests as medical devices, it could require us to conduct additional clinical trials and obtain regulatory approvals for our products, which could harm our business
Updated to reflect that the FDA's final rule regulating Laboratory Developed Tests as medical devices was vacated by a federal court.
Was: If the FDA were to begin to enforce regulation of Laboratory Developed Tests it could require us to conduct additional clinical trials, result in increased costs or delays, or we could fail to obtain necessary regulatory approvals, all of which could harm our business
67% rewrittenRisks Relating to Government Regulation and Reimbursement
The steps we have taken to protect our intellectual property and proprietary rights may not be adequate, which could result in infringement or misappropriation by third parties
Added a note that trademarks will be protected through timely renewal and included trade secret misappropriation claims.
63% rewrittenRisks Relating to Our Business and Operations
The potential loss or delay of our material client contracts could adversely affect our results
Re-titled and kept pharmaceutical development contract termination risks substantially unchanged.
53% rewrittenRisks Related to Our Common Stock and Indebtedness
The capped call transactions may affect the value of the Convertible Notes and our common stock
Updated terminology regarding capped call transactions and Convertible Notes to remove references specifically to the 2028 notes.
Was: The capped call transactions may affect the value of the 2028 Convertible Notes and our common stock
48% rewrittenRisks Related to Our Common Stock and Indebtedness
Servicing our Convertible Notes requires a significant amount of cash. We may not have sufficient cash flow from our business to pay our obligations under the Convertible Notes, which could adversely affect our financial condition and operating results
Removed mention of the 2025 Convertible Notes and specified the 0.25% interest rate on the remaining $345.0 million notes.
38% rewrittenRisks Related to Our Common Stock and Indebtedness
We may not have the ability to raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the Convertible Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes
Clarified that fundamental change repurchase prices for Convertible Notes are paid in cash as defined in the indenture.
36% rewrittenRisks Relating to Government Regulation and Reimbursement
If goodwill and intangible assets that we recorded in connection with our acquisitions become impaired, we may have to take significant charges against earnings
Retained standard goodwill and intangible asset impairment risks without substantive changes to the core language.
29% rewrittenRisks Relating to Our Business and Operations
We face the risk of capacity constraints, which could have a material adverse effect on our business, results of operations, and financial condition
28% rewrittenRisks Relating to Our Business and Operations
We depend substantially upon third parties for payment of services, which reliance could have a material adverse effect on our cash flows and results of operations
27% rewrittenRisks Relating to Our Business and Operations
We expect to make significant investments in the development of new genetic and diagnostic tests and other future products. New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all
Was: We expect to make significant investments in the development of new genetic tests and other future products. New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all
27% rewrittenRisks Related to Our Common Stock and Indebtedness
Conversion of the Convertible Notes may dilute the ownership interest of our existing stockholders or may otherwise adversely effect the market price of our common stock
Was: Conversion of the Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock
25% rewrittenRisks Relating to Government Regulation and Reimbursement
We may incur greater costs than anticipated in connection with implementing our business strategy, which could result in sustained losses
24% rewrittenRisks Relating to Our Business and Operations
Performance issues, service interruptions, or price increases by our shipping carrier could adversely affect our business, results of operations, and financial condition, and harm our reputation and ability to provide our specialized clinical services on a timely basis

All 41 risk factors

Headings as the filing states them, in filing order.

Risks Relating to Our Business and Operations

01We are dependent on key personnel and need to hire additional qualified personnel in order for our business to succeed
02If we are unable to keep pace with the rapid scientific and technological change characteristic to our industry, or to develop, or acquire licenses for, new or improved testing technologies, our competitive position, business, results of operations, and financial condition could be harmed
03We face the risk of capacity constraints, which could have a material adverse effect on our business, results of operations, and financial condition29% rewritten
04If our products do not meet the expectations of our clients and patients, our reputation, business and operating results could sufferNew
05Increased competition, including price competition, could have a material adverse impact on our net revenues and profitability
06We expect to make significant investments in the development of new genetic and diagnostic tests and other future products. New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all27% rewritten
07Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests
08The potential loss or delay of our material client contracts could adversely affect our results63% rewritten
09We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business90% rewritten
10Our provision of laboratory testing and related services in support of sponsor-led clinical trials and research studies may expose us to contractual, operational, regulatory, or reputational risks, including risks related to data integrity, turnaround times, and compliance with applicable quality standardsNew
11clinical trials in accordance with the FDA, the U.S. Drug Enforcement Agency (“DEA”), and other applicable regulations, including good clinical practice and informed consent requirements, could result in disruptions to our operationsNew
12Other manufacturers may discontinue or recall testing products used in our business
13We depend substantially upon third parties for payment of services, which reliance could have a material adverse effect on our cash flows and results of operations28% rewritten
14Business disruptions, including due to natural disasters, power loss, break-ins, global conflicts, political unrest, or unstable economic and market conditions, could have a material adverse effect on our business, results of operations, financial condition, and stock priceNew
15International trade disputes, including United States trade tariffs and retaliatory tariffs, could adversely impact our overall financial condition, results of operations, or cash flowsNew
16We depend on third parties for our laboratory and research equipment and supplies. If these supplies or services become unavailable or are disrupted, we would have to seek alternate suppliers, and we may not be able to successfully perform our research, operate our business, or perform our tests on a timely basisNew
17Our current and potential future use of artificial intelligence and machine learning may not be successful and introduces emerging risks and challenges to our businessNew
18including protected health information. AI and machine learning technologies may also contribute to novel and urgent cybersecurity risks, including through the use by third parties of such technologies to launch more automated, targeted, and coordinated attacksNew
19Performance issues, service interruptions, or price increases by our shipping carrier could adversely affect our business, results of operations, and financial condition, and harm our reputation and ability to provide our specialized clinical services on a timely basis24% rewritten
20We use biological and hazardous materials that require considerable expertise and expense for handling, storage, or disposal and may result in claims against us
21If we are unable to successfully manage the implementation of our Laboratory Information Management System (“LIMS”), our business and results of operations may be adversely affectedNew

Risks Related to Our Common Stock and Indebtedness

22The price of our common stock has, and may continue to, fluctuate significantly
23Servicing our Convertible Notes requires a significant amount of cash. We may not have sufficient cash flow from our business to pay our obligations under the Convertible Notes, which could adversely affect our financial condition and operating results48% rewritten
24We may not have the ability to raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the Convertible Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes38% rewritten
25The capped call transactions may affect the value of the Convertible Notes and our common stock53% rewritten
26Conversion of the Convertible Notes may dilute the ownership interest of our existing stockholders or may otherwise adversely effect the market price of our common stock27% rewritten

Risks Relating to Government Regulation and Reimbursement

27If the FDA were to begin to regulate Laboratory Developed Tests as medical devices, it could require us to conduct additional clinical trials and obtain regulatory approvals for our products, which could harm our business71% rewritten
28Healthcare reform efforts may impact our business and the pricing we receive for our services
29We face efforts by government payers to reduce utilization as well as reimbursement for laboratory testing services. Changes in governmental reimbursement may result from statutory and regulatory changes, prospective and/or retroactive rate adjustments, administrative rulings, and other policy changes
30Our net revenue will be diminished if payers do not adequately cover or reimburse our services
31Our operations are subject to strict laws prohibiting fraudulent billing and other abuse, and our failure to comply with such laws could result in substantial penalties, including exclusion from participation in Medicare, Medicaid, and other governmental payer programs
32The failure to comply with fraud and abuse laws, including physician self-referral laws and anti-kickback laws, may subject us to liability, penalties, or limitation of operations
33Failure to comply with federal, state and international laws related to privacy and security could result in fines, penalties, and damage to the Company’s reputation with clients and could have a material adverse effect upon the Company’s business
34We may not be able to implement our business strategy, which could impair our ability to continue operations
35We may form strategic partnerships or make investments in companies or technologies that could negatively affect our operating results, distract management’s attention from other business concerns, dilute our stockholders’ ownership, and significantly increase our debt, costs, expenses, liabilities and risksNew
36investments in other companies, which could have a material negative effect on our results of operations and financial conditionNew
37If we are unable to successfully integrate future acquisitions with our business, the anticipated benefits of such transactions may not be realized and our business, financial conditions, results of operations and cash flows may be adversely affected
38If goodwill and intangible assets that we recorded in connection with our acquisitions become impaired, we may have to take significant charges against earnings36% rewritten
39We may incur greater costs than anticipated in connection with implementing our business strategy, which could result in sustained losses25% rewritten
40We may face fluctuations in our results of operations and we are subject to seasonality in our business which could negatively affect our business operations
41The steps we have taken to protect our intellectual property and proprietary rights may not be adequate, which could result in infringement or misappropriation by third parties67% rewritten

Other Neogenomics 10-Ks

FY2024 10-K risk factors
37 risks
Neogenomics faces intense competition in genetic and molecular testing from established laboratories like Quest and LabCorp.
Filed Feb 18, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.